Perspective Therapeutics, Inc.
Price data unavailable
Track CATX in your trading journalAbout Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. (CATX) is a publicly listed company on US equity markets.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
The company reports trailing twelve-month revenue of $2.19M and net loss of $26.19M.
Key metrics include a return on equity of -7.5%, a debt-to-equity ratio of 0.18.
Use FINOTAUR to track CATX's price action, review fundamentals, and stay current with company news — all in one research dashboard.
Fundamentals
| Revenue (TTM) | $2.19M |
| Net Income (TTM) | $-26.19M |
| EPS (TTM) | — |
| P/E Ratio | — |
| Return on Equity | -7.54% |
| Debt-to-Equity | 0.18 |
| Dividend per Share | — |
Recent News
- GlobeNewswire Inc.·May 21
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
- GlobeNewswire Inc.·Apr 20
Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsight
- GlobeNewswire Inc.·Apr 20
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting
Want real-time analysis on CATX?
Track it free in your trading journal. Log trades, tag setups, and review your edge.